In the most extensive phase 3 trial, SCF was used for stem cell mobilization: patients received recombinant SCF at 20 μg/kg per day for 5 consecutive days and 3 of them reported systemic allergic reactions, resolved after treatment with steroids81. Here, KITLG is linked to allergic disease.